Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Sell
16
IMUX Quote, Financials, Valuation and Earnings
Last price:
$0.68
Seasonality move
:
-19.79%
Day range:
$0.66 - $0.70
52-week range:
$0.56 - $1.39
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
7.67x
Volume:
729.7K
Avg. volume:
1.2M
1-year change:
-47.7%
Market cap:
$80.5M
Revenue:
--
EPS (TTM):
-$0.87
Analysts' Opinion
-
Consensus RatingImmunic, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.38, Immunic, Inc. has an estimated upside of 702.84% from its current price of $0.67.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.00 representing 100% downside risk from its current price of $0.67.
Fair Value
-
According to the consensus of 9 analysts, Immunic, Inc. has 702.84% upside to fair value with a price target of $5.38 per share.
IMUX vs. S&P 500
-
Over the past 5 trading days, Immunic, Inc. has underperformed the S&P 500 by -1.35% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Immunic, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Immunic, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Immunic, Inc. reported revenues of --.
Earnings Growth
-
Immunic, Inc. has grown year-over-year earnings for 11 quarters straight. In the most recent quarter Immunic, Inc. reported earnings per share of -$0.13.
Enterprise value:
46.2M
EV / Invested capital:
4.09x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.52x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$161K
Return On Assets:
-225.71%
Net Income Margin (TTM):
--
Return On Equity:
-521.65%
Return On Invested Capital:
-498.2%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$107K | -$122K | -$161K | -$42K | -$40K | |
| Operating Income | -$100.2M | -$95.8M | -$105.5M | -$25.7M | -$26M | |
| EBITDA | -$100.1M | -$95.7M | -$105.4M | -$25.7M | -$26M | |
| Diluted EPS | -$3.26 | -$1.24 | -$0.87 | -$0.24 | -$0.13 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $122.5M | $86.6M | $65.2M | $63.3M | $39.3M | |
| Total Assets | $156.8M | $121.1M | $67M | $64.8M | $40.7M | |
| Current Liabilities | $10.6M | $11.5M | $17.8M | $23.4M | $30.1M | |
| Total Liabilities | $11.3M | $12.3M | $18.6M | $23.5M | $30.2M | |
| Total Equity | $145.5M | $108.8M | $48.4M | $41.2M | $10.5M | |
| Total Debt | $1.1M | $759K | $789K | $186K | $126K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$71.9M | -$75.8M | -$89.5M | -$20.8M | -$20.1M | |
| Cash From Investing | -$1K | -$426K | -$153K | -$50K | -$67K | |
| Cash From Financing | $56.5M | $75.1M | $65.6M | -- | -- | |
| Free Cash Flow | -$72.1M | -$76.3M | -$89.6M | -$20.9M | -$20.2M | |
IMUX
Sector
Market Cap
$80.5M
$28.5M
Price % of 52-Week High
48.17%
51.43%
Dividend Yield
0%
0%
Shareholder Yield
-75.39%
-1.33%
1-Year Price Total Return
-47.7%
-21.18%
Beta (5-Year)
1.479
0.519
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.68
200-day SMA
Sell
Level
$0.91
Bollinger Bands (100)
Sell
Level
0.74 - 0.94
Chaikin Money Flow
Sell
Level
-9.5M
20-day SMA
Sell
Level
$0.71
Relative Strength Index (RSI14)
Sell
Level
41.80
ADX Line
Sell
Level
34.25
Williams %R
Neutral
Level
-73.2203
50-day SMA
Sell
Level
$0.78
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Sell
Level
-16M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-22.522)
Sell
CA Score
(Annual)
Level (-9.7661)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (14.8582)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company was founded in May 2003 and is headquartered in New York, NY.
Stock Forecast FAQ
In the current month, IMUX has received 9 Buy ratings 0 Hold ratings, and 0 Sell ratings. The IMUX average analyst price target in the past 3 months is $5.38.
-
Where Will Immunic, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Immunic, Inc. share price will rise to $5.38 per share over the next 12 months.
-
What Do Analysts Say About Immunic, Inc.?
Analysts are divided on their view about Immunic, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Immunic, Inc. is a Sell and believe this share price will drop from its current level to $3.00.
-
What Is Immunic, Inc.'s Price Target?
The price target for Immunic, Inc. over the next 1-year time period is forecast to be $5.38 according to 9 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is IMUX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Immunic, Inc. is a Buy. 9 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of IMUX?
You can purchase shares of Immunic, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Immunic, Inc. shares.
-
What Is The Immunic, Inc. Share Price Today?
Immunic, Inc. was last trading at $0.68 per share. This represents the most recent stock quote for Immunic, Inc.. Yesterday, Immunic, Inc. closed at $0.67 per share.
-
How To Buy Immunic, Inc. Stock Online?
In order to purchase Immunic, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get IMUX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
IMUX
Sector
P/E ratio
--
23.66x
PEG ratio
--
-0.01x
P/B ratio
7.67x
1.82x
Price / LTM sales
--
1.61x
Growth Metrics
IMUX
Sector
Revenue growth
--
4.8%
Earnings growth
45.18%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.18
-$0.20
Profitability
IMUX
Sector
Profitability FY 2024
-$134K
$3.6M
Return on invested capital
-498.2%
-31.15%
Return on assets
-225.71%
-27.72%
Return on equity
-521.65%
-36.72%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Feb
18
Estimated Next Earnings Date
Feb
12
Balance Sheet
IMUX
Sector
Total cash
$35.1M
$27M
Short term investments
--
$25.7M
Total assets
$40.9M
$79.7M
Long term debt
$126K
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
67
GPCR alert for Dec 9
Structure Therapeutics, Inc. [GPCR] is down 2.47% over the past day.
Buy
62
SMX alert for Dec 9
SMX (Security Matters) Plc [SMX] is down 0.6% over the past day.
Buy
90
KYMR alert for Dec 9
Kymera Therapeutics, Inc. [KYMR] is down 7.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
